92 related articles for article (PubMed ID: 21544629)
1. Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
Takeuchi A; Shiota M; Tatsugami K; Yokomizo A; Eto M; Inokuchi J; Kuroiwa K; Kiyoshima K; Naito S
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1557-64. PubMed ID: 21544629
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
Takeuchi A; Eto M; Tatsugami K; Yamada H; Oki T; Kiyoshima K; Yoshikai Y; Naito S
J Urol; 2010 Dec; 184(6):2549-56. PubMed ID: 21030044
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
6. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
7. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
Kawazoe H; Bilim VN; Ugolkov AV; Yuuki K; Naito S; Nagaoka A; Kato T; Tomita Y
Biochem Biophys Res Commun; 2012 Jul; 423(3):490-5. PubMed ID: 22683636
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo.
Kuo YC; Lin WC; Chiang IT; Chang YF; Chen CW; Su SH; Chen CL; Hwang JJ
Biomed Pharmacother; 2012 Feb; 66(1):12-20. PubMed ID: 22265104
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism.
Cai JP; Chen W; Hou X; Liang LJ; Hao XY; Yin XY
Anticancer Drugs; 2013 Nov; 24(10):1020-9. PubMed ID: 23941814
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
Amagai Y; Matsumoto M; Hojo K; Iguchi M; Wada T; Tanaka H; Ide N; Kato A; Shichijo M; Abe K
Jpn J Clin Oncol; 2010 Jun; 40(6):503-7. PubMed ID: 20106881
[TBL] [Abstract][Full Text] [Related]
12. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
13. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
15. Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation.
Sprio AE; Di Scipio F; Ceppi P; Salamone P; Di Carlo F; Scagliotti GV; Papotti M; Ceccarelli A; Berta GN
Cancer Chemother Pharmacol; 2012 Apr; 69(4):983-9. PubMed ID: 22139443
[TBL] [Abstract][Full Text] [Related]
16. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
Hakimé A; Hines-Peralta A; Peddi H; Atkins MB; Sukhatme VP; Signoretti S; Regan M; Goldberg SN
Radiology; 2007 Aug; 244(2):464-70. PubMed ID: 17641366
[TBL] [Abstract][Full Text] [Related]
17. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
19. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
[TBL] [Abstract][Full Text] [Related]
20. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]